Home Immunology & Inflammation Fungal inhibitor - DNA/RNA Synthesis inhibitor Cycloheximide For research use only.

Cycloheximide

Synonyms: NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80

Cycloheximide, an antifungal antibiotic, is an eukaryote protein synthesis inhibitor with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively. Cycloheximide suppresses ferroptosis and inhibits autophagy.Solutions are unstable and should be fresh-prepared.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.

Cycloheximide Chemical Structure

Cycloheximide Chemical Structure

CAS: 66-81-9

Selleck's Cycloheximide has been cited by 273 publications

Purity & Quality Control

Batch: Purity: 99.96%
99.96

Related compound libraries

Choose Selective Fungal Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CEM Anticancer assay Tested in vitro for anticancer activity against CEM cells, IC50 = 0.12 μM. 10072683
9L Anticancer assay Tested in vitro for anticancer activity against 9L cells, IC50 = 0.2 μM. 10072683
SK-MEL-28 Anticancer assay Tested in vitro for anticancer activity against SK-MEL-28 cells, IC50 = 1 μM. 10072683
Vero Cytotoxicity assay Tested in vitro for cytotoxicity against Vero cells, IC50 = 1.2 μM. 10072683
LNCaP Anticancer assay Tested in vitro for anticancer activity against LNCaP cells, IC50 = 1.2 μM. 10072683
MCF-7 Anticancer assay Tested in vitro for anticancer activity against MCF-7 cells, IC50 = 1.5 μM. 10072683
PBM Cytotoxicity assay Tested in vitro for cytotoxicity against PBM cells, IC50 = 2.1 μM. 10072683
HepG2 Anticancer assay Tested in vitro for anticancer activity against HepG2 cells, IC50 = 2.5 μM. 10072683
SK-MES-1 Anticancer assay Tested in vitro for anticancer activity against SK-MES-1 cells, IC50 = 2.7 μM. 10072683
PC-3 Anticancer assay Tested in vitro for anticancer activity against PC-3 cells, IC50 = 3.5 μM. 10072683
Jurkat T-cells Function assay Inhibitory concentration against Human Jurkat T cells, IC50 = 0.93 μM. 10212121
Jurkat T-cells Function assay Inhibitory concentration against Human Jurkat T cells, IC80 = 1.54 μM. 10212121
Jurkat T-cells Function assay 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.93 μM. 11052798
Jurkat T-cells Function assay 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC80 = 1.54 μM. 11052798
CEM Cytotoxicity assay Cytotoxicity was determined in CEM cells, relative to RVT, IC50 = 0.08 μM. 15081000
PBM Cytotoxicity assay Cytotoxicity was determined in PBM cells, relative to RVT, IC50 = 0.46 μM. 15081000
Vero Cytotoxicity assay Cytotoxicity was determined in Vero cells, relative to RVT, IC50 = 0.53 μM. 15081000
HeLa Function assay Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay, IC50 = 0.036 μM. 15974627
medulloblastoma cells Antiproliferative assay Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay, EC50 = 0.042 μM. 17417631
neural precursor cells Antiproliferative assay Antiproliferative activity against mouse neural precursor cells by colony formation assay, EC50 = 0.054 μM. 17417631
astrocyte cells Antiproliferative assay Antiproliferative activity against mouse astrocyte cells by MTT assay, EC50 = 0.071 μM. 17417631
neural precursor cells Antiproliferative assay Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50 = 0.142 μM. 17417631
HeLa Cytotoxicity assay 24 hrs Cytotoxicity against human HeLa cells after 24 hrs, CD50 = 0.1 μM. 18394884
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.912 μM. 18771242
HeLa Function assay 2 hrs Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5325 μM. 20118940
HeLa Function assay 2 hrs Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 2.8801 μM. 20118940
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 20356064
BESM Function assay 88 hrs Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50 = 0.4 μM. 20547819
NIH/3T3 Cytotoxicity assay 48 hrs Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay, IC50 = 1.1 μM. 21899268
MDA-MB-231 Cytotoxicity assay 48 hrs Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 1.2 μM. 21899268
AGS Cytotoxicity assay 48 hrs Cytotoxicity against human AGS cells after 48 hrs by MTT assay, IC50 = 3.6 μM. 21899268
HT-29 Cytotoxicity assay 48 hrs Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 12.8 μM. 21899268
HepG2-A16-CD81 Function assay 10 uM NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration, IC50 = 0.0781 μM. 22096101
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 22437110
HepG2 Function assay HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 0.047 μM. 22586124
PA1 Cytotoxicity assay 24 hrs Cytotoxicity against human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. 23202484
PA1 Growth inhibition assay 24 hrs Growth inhibition of human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. 28011220
3T3 Cytotoxicity assay Cytotoxicity against mouse 3T3 cells by SRB assay, IC50 = 0.3 μM. 29247859
CEM Cytotoxicity assay 5 days Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay, IC50 = 0.2 μM. 29778528
Vero Cytotoxicity assay 3 days Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay, IC50 = 0.2 μM. 29778528
3T3 Cytotoxicity assay 48 hrs Cytotoxicity against rat 3T3 cells after 48 hrs by MTT assay, IC50 = 0.61 μM. 30146096
MCF7 Function assay 10 ug/mL 1 hr Inhibition of HIF1alpha RNA translation in human MCF7 cells at 10 ug/mL pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis 22607231
AGS Apoptosis assay 150 ug/mL 48 hrs Induction of apoptosis in human AGS cells assessed as early apoptosis level at 150 ug/mL after 48 hrs by Annexin V-FITC apoptosis assay 21899268
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells 29435139
T47D Function assay 10 uM 4 hrs Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting 15974627
T47D Function assay 0.3 uM 4 hrs Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting 15974627
T47D Function assay 3 uM 16 hrs Inhibition of hypoxia-induced HIF1 activation in human T47D cells at 3 uM after 16 hrs by luciferase reporter gene assay 15974627
T47D Function assay 0.7 uM 16 hrs Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells at 0.7 uM after 16 hrs by luciferase reporter gene assay 15974627
T47D Function assay 10 uM 16 hrs Inhibition of hypoxia-induced VEGF expression in human T47D cells at 10 uM after 16 hrs by ELISA 15974627
T47D Function assay 0.3 uM 4 hrs Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting 15974627
T47D Function assay 10 uM 4 hrs Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting 15974627
neural precursor cells Function assay 3 uM Induction of neurosphere phenotype changes in mouse neural precursor cells at 3 uM 17417631
HeLa Cytotoxicity assay Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis 18066055
HeLa Function assay Inhibition of mitosis in human HeLa cells by imaging analysis 18066055
HEK293T Function assay 50 uM 30 mins Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 50 uM after 30 mins by spectrophotometry 20118940
T47D Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human T47D cells at 10 uM after 48 hrs by SRB assay 23434131
MDA-MB-231 Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay 23434131
NCI-H460 Function assay 10 ug/mL up to 9 hrs Reduction of HSP1 stability in human NCI-H460 cells assessed as protein degradation at 10 ug/mL up to 9 hrs by Western blot analysis 24746225
HeLa Cytotoxicity assay 25 uM 18 hrs Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay 25028062
RAW264.7 Function assay 70 uM 6 hrs Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 70 uM after 6 hrs by luciferase reporter gene assay 25667960
Click to View More Cell Line Experimental Data

Biological Activity

Description Cycloheximide, an antifungal antibiotic, is an eukaryote protein synthesis inhibitor with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively. Cycloheximide suppresses ferroptosis and inhibits autophagy.Solutions are unstable and should be fresh-prepared.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
In vitro
In vitro

Cyclohexamide, a protein synthesis inhibitor, reduces GSIV-induced host cell death by attenuating phosphatidylserine exposure and loss of ΔΨm from apoptosis/necrosis.[1]
Cell Research Cell lines grouper fin cell line (GF-1)
Concentrations 0.33 µg/ml
Incubation Time 0-5 days
Method

Monolayers of GF-1 cells (4.0 mL, 105 cells/mL) on 60-mm Petri dishes are cultivated for at least 20 h, rinsed twice with phosphate buffered saline (PBS), treated with the protein synthesis inhibitor cycloheximide (CHX, 0.33 µg/mL) and ANT inhibitor BKA (20 µM) for 0 5 days, then infected with GSIV K1 strain (multiplicity of infection [m.o.i. ] = 5) for 0 5 days post-infection (dpi). At the end of the incubation period, each sample is removed from the medium and washed with PBS. Cells are then incubated for 10-15 min with 100 µL staining solution.
Experimental Result Images Methods Biomarkers Images PMID
Western blot β-catenin / MSX2 LIFR / gp130 / TfR BIP / P-P70S6K / P62 / ATF4 / Actin / LC3-I / LC3-II CYP87A3 ERK3 / IRP2 12095419
RNA blot PDI-2 / tubulin / rRNA LEF1 / Cyc-D1 / IGF-1 / HGF / VEGF / KGF / GAPDH 18713834
Immunofluorescence SCD6 / DHH1 / XRNA α-eIF3 / α-Dcp1 TUNEL Rpl25 / Nhp6 β-Catenin 18713834
In Vivo
In vivo

Cycloheximide, a protein synthesis inhibitors, acts on memory by altering modulators of memory formation as a secondary consequence of the inhibition of protein synthesis.[2]
Animal Research Animal Models Male ICR mice
Dosages 30mg/kg, 60mg/kg,120 mg/kg
Administration i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03700788 Not yet recruiting Apical Periodontitis University of Southern California May 30 2023 Phase 3
NCT05506566 Recruiting Tumor|Positron-Emission Tomography First Affiliated Hospital of Fujian Medical University May 1 2022 Phase 1|Phase 2
NCT02202304 Withdrawn Periodontal Disease|Caries Rosa Moreno Lopez|Ivoclar Vivadent AG|University of Aberdeen September 10 2017 Phase 4
NCT01521325 Completed Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer Morphotek September 2011 Phase 1
NCT02168374 Completed Dental Caries Aline R F de Castilho|Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas Brazil March 2008 Phase 2

Chemical lnformation & Solubility

Molecular Weight 281.35 Formula

C15H23NO4
CAS No. 66-81-9 SDF --
Smiles CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C
Storage (From the date of receipt) 3 years-21°C powder Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.

In vitro
Batch:

DMSO : 56 mg/mL ( (199.04 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 56 mg/mL

Water : 15 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Cycloheximide | Cycloheximide supplier | purchase Cycloheximide | Cycloheximide cost | Cycloheximide manufacturer | order Cycloheximide | Cycloheximide distributor